CDP 850

Drug Profile

CDP 850

Latest Information Update: 12 Jan 1999

Price : $50

At a glance

  • Originator Celltech Group
  • Class Antipsoriatics; Monoclonal antibodies
  • Mechanism of Action E-selectin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Psoriasis

Most Recent Events

  • 12 Jan 1999 A phase I/II study in patients with moderate to severe psoriasis has been added to the Skin Disorders therapeutic section
  • 12 Jan 1999 Discontinued-II for Psoriasis in United Kingdom (Topical)
  • 15 Jan 1997 Phase-II clinical trials for Psoriasis in United Kingdom (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top